Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension
Aim. To assess the potential of the angiotensin II receptor antagonist losartan for the correction of hyperuricemia (HU) in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. This open, randomised, controlled comparative study in parallel groups included 60 A...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2011-12-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1958 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849342148118315008 |
|---|---|
| author | S. V. Nedogoda E. V. Chumachok A. A. Ledyaeva V. V. Tsoma |
| author_facet | S. V. Nedogoda E. V. Chumachok A. A. Ledyaeva V. V. Tsoma |
| author_sort | S. V. Nedogoda |
| collection | DOAJ |
| description | Aim. To assess the potential of the angiotensin II receptor antagonist losartan for the correction of hyperuricemia (HU) in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. This open, randomised, controlled comparative study in parallel groups included 60 AH patients with MS and HU. The patients received losartan or standard therapy for 12 weeks. Results. Throughout the follow-up period, no significant difference in antihypertensive effect was observed between the losartan and standard therapy groups. Losartan group patients demonstrated a more pronounced decrease in uric acid levels (-34,7 % vs. -7,8 % in the standard therapy group; p<0,05). In addition, losartan therapy, compared to the standard treatment, was associated with improved vascular elasticity, as manifested by the pulse wave velocity decrease (-27,8 % vs. -8,1 % for carotid-femoral index, and -30,2 % vs. -12,6 % for carotidradial index, respectively; both p<0,05). |
| format | Article |
| id | doaj-art-b72e643365c04007adfe06c5fb3351bb |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2011-12-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-b72e643365c04007adfe06c5fb3351bb2025-08-20T03:43:29Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252011-12-01106242910.15829/1728-8800-2011-6-24-291670Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertensionS. V. Nedogoda0E. V. Chumachok1A. A. Ledyaeva2V. V. Tsoma3Volgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityAim. To assess the potential of the angiotensin II receptor antagonist losartan for the correction of hyperuricemia (HU) in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. This open, randomised, controlled comparative study in parallel groups included 60 AH patients with MS and HU. The patients received losartan or standard therapy for 12 weeks. Results. Throughout the follow-up period, no significant difference in antihypertensive effect was observed between the losartan and standard therapy groups. Losartan group patients demonstrated a more pronounced decrease in uric acid levels (-34,7 % vs. -7,8 % in the standard therapy group; p<0,05). In addition, losartan therapy, compared to the standard treatment, was associated with improved vascular elasticity, as manifested by the pulse wave velocity decrease (-27,8 % vs. -8,1 % for carotid-femoral index, and -30,2 % vs. -12,6 % for carotidradial index, respectively; both p<0,05).https://cardiovascular.elpub.ru/jour/article/view/1958hyperuricemiaarterial hypertensionpulse wave velocitylosartan |
| spellingShingle | S. V. Nedogoda E. V. Chumachok A. A. Ledyaeva V. V. Tsoma Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension Кардиоваскулярная терапия и профилактика hyperuricemia arterial hypertension pulse wave velocity losartan |
| title | Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension |
| title_full | Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension |
| title_fullStr | Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension |
| title_full_unstemmed | Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension |
| title_short | Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension |
| title_sort | losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension |
| topic | hyperuricemia arterial hypertension pulse wave velocity losartan |
| url | https://cardiovascular.elpub.ru/jour/article/view/1958 |
| work_keys_str_mv | AT svnedogoda losartantherapyandhyperuricemiacorrectioninpatientswithmetabolicsyndromeandarterialhypertension AT evchumachok losartantherapyandhyperuricemiacorrectioninpatientswithmetabolicsyndromeandarterialhypertension AT aaledyaeva losartantherapyandhyperuricemiacorrectioninpatientswithmetabolicsyndromeandarterialhypertension AT vvtsoma losartantherapyandhyperuricemiacorrectioninpatientswithmetabolicsyndromeandarterialhypertension |